Technical Analysis for GNTA - Genenta Science S.p.A.

Grade Last Price % Change Price Change
C 10.1455 -2.88% -0.30
GNTA closed down 2.88 percent on Thursday, January 20, 2022, on 1.3 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical GNTA trend table...

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Inside Day Range Contraction -6.06%
Up 3 Days in a Row Strength -6.06%
Multiple of Ten Bullish Other -3.28%
Multiple of Ten Bearish Other 1.96%
Inside Day Range Contraction 1.96%
New 52 Week Closing Low Bearish 3.21%
Hot IPO Pullback Bullish Swing Setup 3.21%
Multiple of Ten Bearish Other 3.21%
Older End-of-Day Signals for GNTA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 1 day ago
Rose Above Previous Day's High 1 day ago
Down 1% 1 day ago
Up 1% 1 day ago
10 DMA Resistance 3 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Gene Therapy Cell Biology Glioblastoma Platform Technology Solid Tumor Cancers Brain Tumor Glioblastoma Multiforme

Is GNTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.13
52 Week Low 9.1
Average Volume 29,054
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 10.96
10-Day Moving Average 10.51
Average True Range 0.89
ADX 0.0
+DI 16.88
-DI 21.83
Chandelier Exit (Long, 3 ATRs) 10.46
Chandelier Exit (Short, 3 ATRs) 11.77
Upper Bollinger Bands 12.16
Lower Bollinger Band 9.75
Percent B (%b) 0.16
BandWidth 22.01
MACD Line -0.38
MACD Signal Line -0.27
MACD Histogram -0.1095
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.95
Resistance 3 (R3) 11.94 11.32 11.65
Resistance 2 (R2) 11.32 10.86 11.33 11.55
Resistance 1 (R1) 10.73 10.58 11.03 10.75 11.45
Pivot Point 10.12 10.12 10.26 10.12 10.12
Support 1 (S1) 9.53 9.66 9.82 9.54 8.84
Support 2 (S2) 8.91 9.37 8.92 8.74
Support 3 (S3) 8.33 8.91 8.64
Support 4 (S4) 8.34